TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin

Neuroscience Letters

Volumn 442, Issue 2, 2008, Pages 109-113

  Gaiser, T ^a   Becker, M R ^a   Habel, A ^a   Reuss, D E ^b   Ehemann, V ^a   Rami, A ^c   Siegelin, M D ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Celecoxib; Glioma; Proteasome; Survivin; TRAIL Apo2L

Indexed keywords

CELECOXIB; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

APOPTOSIS; CELL LINE, TUMOR; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PYRAZOLES; SIGNAL TRANSDUCTION; SULFONAMIDES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 48149106737     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.07.014     Document Type: Article

References (32)

1. Altieri D.C. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr. Opin. Cell Biol. 18 (2006) 609-615
2. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. 8 (2008) 61-70
3. Blum R., Jacob-Hirsch J., Rechavi G., and Kloog Y. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol. Cancer Ther. 5 (2006) 2337-2347
4. Chakravarti A., Noll E., Black P.M., Finkelstein D.F., Finkelstein D.M., Dyson N.J., and Loeffler J.S. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J. Clin. Oncol. 20 (2002) 1063-1068
5. Chen W., Wang X., Zhuang J., Zhang L., and Lin Y. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis 28 (2007) 2114-2121
6. Cohen E.G., Almahmeed T., Du B., Golijanin D., Boyle J.O., Soslow R.A., Subbaramaiah K., and Dannenberg A.J. Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma. Clin. Cancer. Res. 9 (2003) 3425-3430
7. Crane C.H., Mason K., Janjan N.A., and Milas L. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am. J. Clin. Oncol. 26 (2003) S81-84
8. Ehemann V., Kern M.A., Breinig M., Schnabel P.A., Gunawan B., Schulten H.J., Schlaeger C., Radlwimmer B., Steger C.M., Dienemann H., Lichter P., Schirmacher P., and Rieker R.J. Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma. Int. J. Cancer 122 (2008) 2719-2725
9. Ehemann V., Sykora J., Vera-Delgado J., Lange A., and Otto H.F. Flow cytometric detection of spontaneous apoptosis in human breast cancer using the TUNEL-technique. Cancer Lett. 194 (2003) 125-131
10. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. 5 (2005) 876-885
11. Fukada K., Takahashi-Yanaga F., Sakoguchi-Okada N., Shiraishi F., Miwa Y., Morimoto S., and Sasaguri T. Celecoxib induces apoptosis by inhibiting the expression of survivin in HeLa cells. Biochem. Biophys. Res. Commun. 357 (2007) 1166-1171
12. Grosch S., Maier T.J., Schiffmann S., and Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 98 (2006) 736-747
13. Grubbs C.J., Lubet R.A., Koki A.T., Leahy K.M., Masferrer J.L., Steele V.E., Kelloff G.J., Hill D.L., and Seibert K. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60 (2000) 5599-5602
14. Hao C., Beguinot F., Condorelli G., Trencia A., Van Meir E.G., Yong V.W., Parney I.F., Roa W.H., and Petruk K.C. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apoptosis in human malignant glioma cells. Cancer Res. 61 (2001) 1162-1170
15. He Q., Luo X., Jin W., Huang Y., Reddy M.V., Reddy E.P., and Sheikh M.S. Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP. Oncogene 27 (2008) 2656-2660
16. Kern M.A., Haugg A.M., Koch A.F., Schilling T., Breuhahn K., Walczak H., Fleischer B., Trautwein C., Michalski C., Schulze-Bergkamen H., Friess H., Stremmel W., Krammer P.H., Schirmacher P., and Muller M. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res. 66 (2006) 7059-7066
17. Kim E.H., Kim H.S., Kim S.U., Noh E.J., Lee J.S., and Choi K.S. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 24 (2005) 6877-6889
18. Kim E.H., Kim S.U., Shin D.Y., and Choi K.S. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 23 (2004) 446-456
19. Liu X., Yue P., Zhou Z., Khuri F.R., and Sun S.Y. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J. Natl. Cancer Inst. 96 (2004) 1769-1780
20. Morgillo F., Woo J.K., Kim E.S., Hong W.K., and Lee H.Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 66 (2006) 10100-10111
21. Nesterov A., Lu X., Johnson M., Miller G.J., Ivashchenko Y., and Kraft A.S. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem. 276 (2001) 10767-10774
22. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., and Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139 (1991) 271-279
23. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J., and Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl. J. Med. 351 (2004) 2817-2826
24. Papapetropoulos A., Fulton D., Mahboubi K., Kalb R.G., O'Connor D.S., Li F., Altieri D.C., and Sessa W.C. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J. Biol. Chem. 275 (2000) 9102-9105
25. Reddy B.S., Hirose Y., Lubet R., Steele V., Kelloff G., Paulson S., Seibert K., and Rao C.V. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 60 (2000) 293-297
26. Siddiqui I.A., Malik A., Adhami V.M., Asim M., Hafeez B.B., Sarfaraz S., and Mukhtar H. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 27 (2008) 2055-2063
27. Smith S.D., Wheeler M.A., Plescia J., Colberg J.W., Weiss R.M., and Altieri D.C. Urine detection of survivin and diagnosis of bladder cancer. JAMA 285 (2001) 324-328
28. Stupp R., Hegi M.E., van den Bent M.J., Mason W.P., Weller M., Mirimanoff R.O., and Cairncross J.G. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 11 (2006) 165-180
29. Tran J., Master Z., Yu J.L., Rak J., Dumont D.J., and Kerbel R.S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 4349-4354
30. Velculescu V.E., Madden S.L., Zhang L., Lash A.E., Yu J., Rago C., Lal A., Wang C.J., Beaudry G.A., Ciriello K.M., Cook B.P., Dufault M.R., Ferguson A.T., Gao Y., He T.C., Hermeking H., Hiraldo S.K., Hwang P.M., Lopez M.A., Luderer H.F., Mathews B., Petroziello J.M., Polyak K., Zawel L., and Kinzler K.W. Analysis of human transcriptomes. Nat. Genet. 23 (1999) 387-388
31. Yoshimatsu K., Golijanin D., Paty P.B., Soslow R.A., Jakobsson P.J., DeLellis R.A., Subbaramaiah K., and Dannenberg A.J. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin. Cancer Res. 7 (2001) 3971-3976
32. Zhao J., Tenev T., Martins L.M., Downward J., and Lemoine N.R. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J. Cell. Sci. 113 Part 23 (2000) 4363-4371